LifeSci Advisors
LifeSci Advisors is the largest integrated investor relations firm in healthcare with global operations across North America, Europe, and Israel. They draw from diverse Wall Street, scientific, and communications backgrounds to successfully plan and implement strategic programs for public and private life sciences companies of all sizes and stages. Their mission is to enhance visibility, strategic positioning, and investor engagement for healthcare and biotech companies worldwide.
Industries
Nr. of Employees
small (1-50)
LifeSci Advisors
New York, New York, United States, North America
Products
Corporate Access Event (multi-company investor forum)
Large-scale corporate access events timed for major healthcare conferences that aggregate public and private life-science companies to meet institutional investors, analysts and family offices.
Interactive virtual event platform (webinar/webcast service)
A production and hosting service for interactive virtual events that supports live presentations, Q&A, attendee metrics and replay viewing.
Corporate Access Event (multi-company investor forum)
Large-scale corporate access events timed for major healthcare conferences that aggregate public and private life-science companies to meet institutional investors, analysts and family offices.
Interactive virtual event platform (webinar/webcast service)
A production and hosting service for interactive virtual events that supports live presentations, Q&A, attendee metrics and replay viewing.
Services
Ongoing advisory and program execution including messaging, IR roadmaps, investor outreach and engagement across investor types.
Advisory and execution services for IPOs, SPAC combinations, follow-on offerings and private placements, including banker selection and placement coordination.
Coordination and production of events featuring clinical experts to present clinical data, discuss unmet needs and provide third-party scientific validation.
Organization of multi-company corporate access events, one-on-one investor meetings and multi-city non-deal roadshows to connect management with investors.
Providing placement-agent services and investor introductions to execute milestone-driven private placements and PIPE transactions.
Development and refinement of investor presentations, press releases, call scripts and Q&A materials to support clinical readouts and corporate announcements.
Ongoing advisory and program execution including messaging, IR roadmaps, investor outreach and engagement across investor types.
Advisory and execution services for IPOs, SPAC combinations, follow-on offerings and private placements, including banker selection and placement coordination.
Coordination and production of events featuring clinical experts to present clinical data, discuss unmet needs and provide third-party scientific validation.
Organization of multi-company corporate access events, one-on-one investor meetings and multi-city non-deal roadshows to connect management with investors.
Providing placement-agent services and investor introductions to execute milestone-driven private placements and PIPE transactions.
Development and refinement of investor presentations, press releases, call scripts and Q&A materials to support clinical readouts and corporate announcements.
Expertise Areas
- Investor relations management
- Capital markets advisory (IPO/SPAC/follow-on offerings)
- Investor targeting and outreach (institutional, retail, HNW, family offices)
- Event management for life-science audiences (KOL events, R&D days, corporate access)
Key Technologies
- Virtual event/webinar platforms
- Webcast streaming and replay
- Digital marketing and social media tools
- Investor CRM and targeting lists
News & Updates
LifeSci hosted a KOL event for enVVeno Medical on its lead product VenoValve®, featuring discussions on vascular disease treatment and prospects for commercial adoption. The event attracted 74 live attendees and 52 replay viewers, resulting in a 44.1% increase in stock price and a volume increase of 452.57%.
A virtual KOL event featuring Jonathan Barratt, PhD, FRCP, discussing IgA nephropathy and atacicept’s clinical data. The event contributed to Vera’s stock appreciation of 122.64% from $3.18 to $7.08, and subsequent stock increase to $7.80 (+31%).
BioInvent hosted a virtual event with lymphoma expert Mats Jerkeman MD, discussing treatment landscape and unmet needs. The event led to a share issue raising approximately USD 116 million.
InspireMD completed a private placement of up to $113.6 million and executed a comprehensive IR program including non-deal roadshows, investor targeting, and a series of educational videos, resulting in a market cap increase to over $124 million.
Vyne engaged LifeSci to elevate its investor presence, resulting in a private placement of $88 million, exceeding 8x its market cap, and a stock valuation increase from $8M to $55M USD.
Abivax worked with LifeSci to increase visibility, leading to two oversubscribed financings totaling EUR 179.2 million and a stock price increase from EUR 7.63 to EUR 16.2.
LifeSci hosted a KOL event for enVVeno Medical on its lead product VenoValve®, featuring discussions on vascular disease treatment and prospects for commercial adoption. The event attracted 74 live attendees and 52 replay viewers, resulting in a 44.1% increase in stock price and a volume increase of 452.57%.
A virtual KOL event featuring Jonathan Barratt, PhD, FRCP, discussing IgA nephropathy and atacicept’s clinical data. The event contributed to Vera’s stock appreciation of 122.64% from $3.18 to $7.08, and subsequent stock increase to $7.80 (+31%).
BioInvent hosted a virtual event with lymphoma expert Mats Jerkeman MD, discussing treatment landscape and unmet needs. The event led to a share issue raising approximately USD 116 million.
InspireMD completed a private placement of up to $113.6 million and executed a comprehensive IR program including non-deal roadshows, investor targeting, and a series of educational videos, resulting in a market cap increase to over $124 million.
Vyne engaged LifeSci to elevate its investor presence, resulting in a private placement of $88 million, exceeding 8x its market cap, and a stock valuation increase from $8M to $55M USD.
Abivax worked with LifeSci to increase visibility, leading to two oversubscribed financings totaling EUR 179.2 million and a stock price increase from EUR 7.63 to EUR 16.2.